Lilly(US:LLY) GLP1减重宝典·2025-09-18 10:28Core Viewpoint - The article highlights the positive results of the ACHIEVE-3 study for orforglipron, a once-daily oral GLP-1 receptor agonist, which shows superior efficacy compared to semaglutide in adults with type 2 diabetes [4][6]. Group 1: Study Results - The ACHIEVE-3 trial included 1,698 adults with type 2 diabetes inadequately controlled on metformin, comparing orforglipron (12mg and 36mg) with semaglutide (7mg and 14mg) [6]. - At week 52, orforglipron demonstrated a greater reduction in A1C levels, with decreases of 1.9% and 2.2% for the 12mg and 36mg groups, respectively, compared to 1.1% and 1.4% for semaglutide [6]. - In terms of weight loss, orforglipron resulted in reductions of 6.6kg (6.7%) and 8.9kg (9.2%), while semaglutide led to losses of 3.6kg (3.7%) and 5.0kg (5.3%) [6]. Group 2: Safety and Tolerability - The safety profile of orforglipron was consistent with previous studies, with the most common adverse effects being gastrointestinal symptoms, typically mild to moderate [8]. - The discontinuation rates due to adverse effects were 8.7% for the 12mg group and 9.7% for the 36mg group, compared to 4.5% and 4.9% for the semaglutide groups [8]. Group 3: Drug Profile - Orforglipron is an investigational small molecule, non-peptide GLP-1 receptor agonist that can be taken at any time of day without dietary restrictions [9]. - The drug is being developed by Eli Lilly, which has ongoing phase 3 studies to explore its application in type 2 diabetes and related metabolic complications [9].